Nuria Martín owns a Business and Economic Sciences degree from the University Complutense, Madrid, and also holds a MBA from de Chamber of Commerce. She started her professional career as Accounting Auditor for representative holdings. In 1996, she was named Administrative and Financial Director at LABIPATH, S.A., a clinical analysis laboratory based in Madrid. Two years after, she became CEO and shareholder of the company. She sold her shares in 2005 and continued her career as Director of Planning and Control at Unilabs Iberia. Until then, her expertise was focused on managing, while in this new position she had the opportunity to add new skills in Business Development, M&A and dealing with public-private partnership. In 2010 she joined BR Salud as Managing Director, the first public laboratory in Madrid, providing services to 6 Public Hospitals, covering1.600.000 citizens, and managed in a capitative model. In 2012 she took the lead of Analiza, laboratory participated by Asisa and Marcelo Weisz. Analiza is the fastest growing project in the Spanish market, Nuria Martín currently acts as CEO and Board member. Since 2015, she is also board member of the laboratories APA Centro de Análisis Biologics and Cerba Internacional, where she has been named CEO in 2016.